Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells $44,869.90 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) CAO Rakhi Kumar sold 12,127 shares of the company’s stock in a transaction on Friday, May 20th. The stock was sold at an average price of $3.70, for a total value of $44,869.90. Following the transaction, the chief accounting officer now owns 147,656 shares in the company, valued at $546,327.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Rakhi Kumar also recently made the following trade(s):

• On Monday, April 25th, Rakhi Kumar sold 703 shares of Roivant Sciences stock. The stock was sold at an average price of $3.84, for a total value of $2,699.52.
• On Wednesday, March 30th, Rakhi Kumar sold 2,486 shares of Roivant Sciences stock. The stock was sold at an average price of $4.84, for a total value of $12,032.24.
• On Friday, March 25th, Rakhi Kumar sold 7,281 shares of Roivant Sciences stock. The stock was sold at an average price of $5.06, for a total value of $36,841.86.
• On Friday, March 18th, Rakhi Kumar sold 2,153 shares of Roivant Sciences stock. The stock was sold at an average price of $5.13, for a total value of $11,044.89.
• On Monday, March 7th, Rakhi Kumar sold 3,091 shares of Roivant Sciences stock. The stock was sold at an average price of $5.52, for a total value of $17,062.32.

NASDAQ ROIV traded up $0.26 during trading hours on Tuesday, hitting $3.91. The company had a trading volume of 2,096,503 shares, compared to its average volume of 426,649. Roivant Sciences Ltd. has a 1-year low of $2.52 and a 1-year high of $16.76. The business has a 50 day moving average of $4.13 and a 200-day moving average of $6.45.

A number of analysts have recently weighed in on ROIV shares. The Goldman Sachs Group cut their price objective on Roivant Sciences from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday. Zacks Investment Research lowered Roivant Sciences from a “hold” rating to a “sell” rating in a research report on Friday, February 18th. SVB Leerink assumed coverage on Roivant Sciences in a research report on Monday. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on Roivant Sciences in a report on Friday, April 29th. They issued an “overweight” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.86.

Several institutional investors and hedge funds have recently made changes to their positions in ROIV. SB Investment Advisers UK Ltd. acquired a new stake in shares of Roivant Sciences during the fourth quarter worth about $1,001,706,000. BlackRock Inc. acquired a new stake in shares of Roivant Sciences during the fourth quarter worth about $39,585,000. American International Group Inc. acquired a new stake in shares of Roivant Sciences during the first quarter worth about $8,965,000. Geode Capital Management LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth about $11,694,000. Finally, Eventide Asset Management LLC boosted its stake in shares of Roivant Sciences by 141.5% during the first quarter. Eventide Asset Management LLC now owns 1,690,300 shares of the company’s stock worth $8,177,000 after buying an additional 990,300 shares during the period. Institutional investors and hedge funds own 61.49% of the company’s stock.

About Roivant Sciences (Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Further Reading